Immuneering Corporation (IMRX)
Nasdaq · Healthcare · Biotechnology
$4.04−0.74%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $261M
- 52-week range
- $3.86 – $8.48
- 52-week change
- −35.19%
- EPS (trailing)
- −$0.93
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$56.0M
- Diluted EPS
- −$1.27
- Free cash flow
- −$45.5M
From the company’s annual report on SEC EDGAR.
About Immuneering Corporation
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Headquarters: Cambridge, United States · 57 employees · immuneering.com